MedTrace Logo

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

NCT03198026 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-02-19

No results posted yet for this study

Summary

This phase II trial studies how well obinutuzumab and ibrutinib work as front line therapy in treating patients with indolent non-Hodgkin's lymphoma. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving obinutuzumab and ibrutinib may work better in treating patients with non-Hodgkin's lymphomas.

Conditions

  • Non-Hodgkin's Lymphoma
  • Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
  • Ann Arbor Stage II Follicular Lymphoma
  • Ann Arbor Stage II Nodal Marginal Zone Lymphoma
  • Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma
  • Ann Arbor Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
  • Ann Arbor Stage III Follicular Lymphoma
  • Ann Arbor Stage III Nodal Marginal Zone Lymphoma
  • Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma
  • Ann Arbor Stage IV Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
  • Ann Arbor Stage IV Follicular Lymphoma
  • Ann Arbor Stage IV Nodal Marginal Zone Lymphoma
  • Grade 1 Follicular Lymphoma
  • Grade 2 Follicular Lymphoma
  • Grade 3a Follicular Lymphoma
  • Indolent Non-hodgkin Lymphoma
  • Stage II Splenic Marginal Zone Lymphoma
  • Stage III Splenic Marginal Zone Lymphoma
  • Stage IV Splenic Marginal Zone Lymphoma

Interventions

DRUG

Ibrutinib

Given PO

BIOLOGICAL

Obinutuzumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Pharmacyclics LLC.

    collaborator INDUSTRY

  • Sidney Kimmel Cancer Center at Thomas Jefferson University

    lead OTHER

Principal Investigators

  • Ubaldo Martinez-Outschoorn, MD · Sidney Kimmel Cancer Center at Thomas Jefferson University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-20
Primary Completion
2026-09-11
Completion
2032-02-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03198026 on ClinicalTrials.gov